HRMY Valuation

Harmony Biosciences Holdings Inc

Add to Watchlist

Advanced Chart

34.190

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

HRMY Relative Valuation

HRMY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HRMY is overvalued; if below, it's undervalued.

Historical Valuation

Harmony Biosciences Holdings Inc (HRMY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 10.36 is considered Undervalued compared with the five-year average of 23.60. The fair price of Harmony Biosciences Holdings Inc (HRMY) is between 41.09 to 164.12 according to relative valuation methord. Compared to the current price of 34.19 USD , Harmony Biosciences Holdings Inc is Undervalued By 16.8%.

Relative Value

Fair Zone

41.09-164.12

Current Price：34.19

16.8%

Undervalued

10.36

Trailing

Forward

5.21

EV/EBITDA

Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBITDA of 5.21. The 5-year average EV/EBITDA is 12.35. The thresholds are as follows: Strongly Undervalued below -3.81, Undervalued between -3.81 and 4.27, Fairly Valued between 20.43 and 4.27, Overvalued between 20.43 and 28.51, and Strongly Overvalued above 28.51. The current Forward EV/EBITDA of 5.21 falls within the Historic Trend Line -Fairly Valued range.

5.82

EV/EBIT

Harmony Biosciences Holdings Inc. (HRMY) has a current EV/EBIT of 5.82. The 5-year average EV/EBIT is 14.90. The thresholds are as follows: Strongly Undervalued below -7.53, Undervalued between -7.53 and 3.68, Fairly Valued between 26.11 and 3.68, Overvalued between 26.11 and 37.32, and Strongly Overvalued above 37.32. The current Forward EV/EBIT of 5.82 falls within the Historic Trend Line -Fairly Valued range.

2.16

Harmony Biosciences Holdings Inc. (HRMY) has a current PS of 2.16. The 5-year average PS is 4.51. The thresholds are as follows: Strongly Undervalued below 0.11, Undervalued between 0.11 and 2.31, Fairly Valued between 6.71 and 2.31, Overvalued between 6.71 and 8.92, and Strongly Overvalued above 8.92. The current Forward PS of 2.16 falls within the Undervalued range.

6.96

P/OCF

Harmony Biosciences Holdings Inc. (HRMY) has a current P/OCF of 6.96. The 5-year average P/OCF is 16.06. The thresholds are as follows: Strongly Undervalued below -14.47, Undervalued between -14.47 and 0.79, Fairly Valued between 31.32 and 0.79, Overvalued between 31.32 and 46.58, and Strongly Overvalued above 46.58. The current Forward P/OCF of 6.96 falls within the Historic Trend Line -Fairly Valued range.

8.34

P/FCF

Harmony Biosciences Holdings Inc. (HRMY) has a current P/FCF of 8.34. The 5-year average P/FCF is 13.60. The thresholds are as follows: Strongly Undervalued below 1.84, Undervalued between 1.84 and 7.72, Fairly Valued between 19.47 and 7.72, Overvalued between 19.47 and 25.35, and Strongly Overvalued above 25.35. The current Forward P/FCF of 8.34 falls within the Historic Trend Line -Fairly Valued range.

Harmony Biosciences Holdings Inc (HRMY) has a current Price-to-Book (P/B) ratio of 2.54. Compared to its 3-year average P/B ratio of 4.69 , the current P/B ratio is approximately -45.73% higher. Relative to its 5-year average P/B ratio of 8.95, the current P/B ratio is about -71.57% higher. Harmony Biosciences Holdings Inc (HRMY) has a Forward Free Cash Flow (FCF) yield of approximately 13.15%. Compared to its 3-year average FCF yield of 9.37%, the current FCF yield is approximately 40.36% lower. Relative to its 5-year average FCF yield of 6.38% , the current FCF yield is about 106.29% lower.

2.54

P/B

Median3y

4.69

Median5y

8.95

13.15

FCF Yield

Median3y

9.37

Median5y

6.38

Competitors Valuation Multiple

The average P/S ratio for HRMY's competitors is 29.33, providing a benchmark for relative valuation. Harmony Biosciences Holdings Inc Corp (HRMY) exhibits a P/S ratio of 2.16, which is -92.65% above the industry average. Given its robust revenue growth of 16.01%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HRMY.O

Harmony Biosciences Holdings Inc

Tarsus Pharmaceuticals Inc

IDEAYA Biosciences Inc

119.01

2.02B

AGIO.O

Agios Pharmaceuticals Inc

Amicus Therapeutics Inc

Performance Decomposition

Market capitalization of HRMY decreased by 4.97% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 6.71 to 19.84.

The secondary factor is the Revenue Growth, contributed 16.01%to the performance.

Overall, the performance of HRMY in the past 1 year is driven by Margin Expansion. Which is more sustainable.

16.01%

172.81M → 200.49M

Revenue Growth

195.68%

6.71 → 19.84

Margin Expansion

-216.66%

-9.47 → 11.04

P/E Change

-4.97%